Cannon Global Investment Management LLC Buys New Position in uniQure N.V. $QURE

Cannon Global Investment Management LLC purchased a new stake in shares of uniQure N.V. (NASDAQ:QURE) during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 12,200 shares of the biotechnology company’s stock, valued at approximately $199,000.

Other large investors have also recently modified their holdings of the company. Woodline Partners LP boosted its holdings in shares of uniQure by 25.0% in the first quarter. Woodline Partners LP now owns 175,806 shares of the biotechnology company’s stock worth $1,864,000 after buying an additional 35,175 shares during the last quarter. Legal & General Group Plc bought a new position in uniQure in the 2nd quarter valued at $497,000. Marshall Wace LLP raised its position in uniQure by 276.5% during the 2nd quarter. Marshall Wace LLP now owns 222,979 shares of the biotechnology company’s stock valued at $3,108,000 after purchasing an additional 163,749 shares in the last quarter. California State Teachers Retirement System bought a new stake in uniQure during the 2nd quarter valued at $540,000. Finally, Ameriprise Financial Inc. grew its position in shares of uniQure by 38.6% in the 2nd quarter. Ameriprise Financial Inc. now owns 761,948 shares of the biotechnology company’s stock worth $10,622,000 after buying an additional 212,218 shares during the last quarter. Hedge funds and other institutional investors own 78.83% of the company’s stock.

Analyst Upgrades and Downgrades

QURE has been the topic of a number of recent research reports. Sanford C. Bernstein lowered uniQure to a “market perform” rating in a research report on Tuesday, March 3rd. TD Cowen reaffirmed a “buy” rating on shares of uniQure in a report on Tuesday, March 3rd. Barclays raised uniQure from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $25.00 to $65.00 in a research report on Thursday, June 18th. Stifel Nicolaus set a $28.00 price objective on shares of uniQure in a report on Tuesday, May 5th. Finally, HC Wainwright restated a “buy” rating on shares of uniQure in a research note on Thursday, June 18th. Twelve research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $61.67.

uniQure Trading Down 3.2%

Shares of uniQure stock opened at $47.51 on Friday. The company has a market capitalization of $3.00 billion, a P/E ratio of -13.65 and a beta of 0.98. uniQure N.V. has a 1 year low of $8.73 and a 1 year high of $71.50. The company’s fifty day moving average is $27.84 and its two-hundred day moving average is $23.02. The company has a debt-to-equity ratio of 0.33, a quick ratio of 10.40 and a current ratio of 10.40.

uniQure (NASDAQ:QURE) last posted its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($0.85) EPS for the quarter, beating the consensus estimate of ($0.88) by $0.03. The firm had revenue of $3.56 million during the quarter, compared to the consensus estimate of $5.21 million. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%. Analysts forecast that uniQure N.V. will post -3.64 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Jack Kaye sold 5,295 shares of the stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $42.57, for a total value of $225,408.15. Following the sale, the director directly owned 25,996 shares of the company’s stock, valued at approximately $1,106,649.72. This represents a 16.92% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Matthew C. Kapusta sold 28,716 shares of the firm’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $50.02, for a total transaction of $1,436,374.32. Following the transaction, the chief executive officer directly owned 519,227 shares of the company’s stock, valued at approximately $25,971,734.54. This trade represents a 5.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 359,546 shares of company stock worth $14,549,943 in the last three months. Company insiders own 4.65% of the company’s stock.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.